Whole Exome Analysis of NIAAA Clinical Center pATIENTS
Closed Pre-Solicitation Posted
- Solicitation number
- 75N98026Q00677
- Agency
-
Office of Logisitics and Acquisition Operations
National Institutes of Health, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- Bethesda, Maryland 20892, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The National Institutes of Health National Institute on Alcohol Abuse and Alcoholism (NIAAA) intends to solicit whole exome sequencing analysis services for its Clinical Center patient cohort, with responses due by July 2, 2026.
The requirement involves analyzing over 2,000 patient samples to identify sequence variant differences and treatment response patterns in alcohol-related disorders. Work must be performed using the AmpliSeq Exome enrichment system and ION sequencing platform—the identical platforms used for previously analyzed samples. Platform consistency is non-negotiable; each sequencing platform produces unique error patterns, and analytical integrity requires all samples in the study to be processed on the same platform to ensure data comparability across samples analyzed at different time points.
Life Technologies Inc. has submitted a Notice of Intent, signaling competitive interest. The procurement carries NAICS 325414 (Biological Product Manufacturing) and PSC 6505 (Drugs and Biologicals). No set-aside applies.
Notice text
The NIAAA Clinical Center patient cohort has been analyzed patients for sequence variant differences, and changes in response to treatment over the course of many years as part of an effort to identify underlying causes of alcohol related disorders. Analysis has previously been performed on over 2000 patients using the AmpliSeq Exome enrichment system and sequenced on the ION sequencing platform because it provides the capability of cost-effective high throughput whole-exome genome-wide analysis. The use of a single enrichment and sequencing platform with consistent information content is essential for analysis of samples screened at different times and it is therefore imperative for analytical integrity that all samples in the study are processed on the same sequencing platform, as each platform has a unique pattern of error
Files
| File | Type | Posted |
|---|---|---|
| Notice of Intent LIFETECHNOLOGIES INC.docx | DOCX document |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| DNA Sequencing Service | Office of Logisitics and Acquisition Operations | No set-aside | |
| Clinical Research Support and Collaboration for NHGRI Protocols | Office of Logisitics and Acquisition Operations | Total Small Business |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity